IP Verse

Preparation Of Solid Dosage Forms Comprising Antibodies By Solution/Suspension Layering - EP3459528

The patent EP3459528 was granted to Tillotts Pharma on Nov 23, 2022. The application was originally filed on Sep 20, 2017 under application number EP17192260A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3459528

TILLOTTS PHARMA
Application Number
EP17192260A
Filing Date
Sep 20, 2017
Status
Opposition Rejected
Mar 28, 2025
Grant Date
Nov 23, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEIROTHAug 22, 2023F & E PATENTADMISSIBLE

Patent Citations (38) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2017EP56218-
DESCRIPTIONWO2017EP56227-
DESCRIPTIONWO2017EP56237-
DESCRIPTIONWO2017EP56246-
DESCRIPTIONEP1037968
DESCRIPTIONEP1643977
DESCRIPTIONEP1684729
DESCRIPTIONEP2390267
DESCRIPTIONEP2512453
DESCRIPTIONGB2246570
DESCRIPTIONGB2297145
DESCRIPTIONGB2367002
DESCRIPTIONUS2014193400
DESCRIPTIONUS5919452
DESCRIPTIONUS6354728
DESCRIPTIONUS8293235
DESCRIPTIONUS8673310
DESCRIPTIONUS8697074
DESCRIPTIONUS9107804
DESCRIPTIONWO0176562
DESCRIPTIONWO03068196
DESCRIPTIONWO2004062577
DESCRIPTIONWO2005046561
DESCRIPTIONWO2005115340
DESCRIPTIONWO2006131013
DESCRIPTIONWO2007122374
DESCRIPTIONWO2009155723
DESCRIPTIONWO9211383
OPPOSITIONEP2777695
OPPOSITIONUS2007026082
OPPOSITIONUS5780028
OPPOSITIONWO2009083607
OPPOSITIONWO2012130872
OPPOSITIONWO2014143085
OPPOSITIONWO9300077
SEARCHWO2009076754
SEARCHWO2012130872
SEARCHWO9945903

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BANSAL et al., Polim. Med., (20140000), vol. 44, no. 2, pages 109 - 118-
DESCRIPTION- FENDLY et al., Hybridoma, (19870000), vol. 6, pages 359 - 370-
DESCRIPTION- MEAGER et al., Hybridoma, (19870000), vol. 6, pages 305 - 311-
DESCRIPTION- STEPHENS et al., Immunology, (19950000), vol. 85, pages 668 - 674-
DESCRIPTION- VARUM et al., Int. J. Pharm., (20100000), vol. 395, no. 1-2, pages 26 - 36-
DESCRIPTION- VERMEER et al., Biophys J., (20000100), vol. 78, no. 1, pages 394 - 404-
DESCRIPTION- YADAV et al., International Journal of Pharmaceutics, (20160000), vol. 502, no. 1- 2, pages 181 - 187-
OPPOSITION- Anonymous, "INFLUENCE OF TRIETHYL CITRATE ON THE PROPERTIES OF TABLETS CONTAINING COATED PELLETS", PHARMACEUTICAL COATINGS BULLETIN 102-4, (20040106), XP093181660-
OPPOSITION- Anonymous, "Modified-release dosage", Wikipedia, (20171025), Wikipedia, URL: https://en.wikipedia.org/w/index.php?title=Modified-release_dosage&oldid=807013582 , XP093181661-
OPPOSITION- Anonymous, "Technical Information EUDRAGIT® L 30 D-55", Eudragit, (20140501), Eudragit, URL: https://www.stobec.com/DATA/PRODUIT/1598~v~data_8595.pdf, XP093181664-
OPPOSITION- Bristol Andrew; Hubert Steven; Hofmann Felix; Baer Hans, "Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (19000101), vol. 534, no. 1, doi:10.1016/j.ijpharm.2017.10.001, ISSN 0378-5173, pages 25 - 34, XP085280587

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents